Teprotumumab for Thyroid-Associated Ophthalmopathy.

MLA

Smith, Terry J., et al. “Teprotumumab for Thyroid-Associated Ophthalmopathy.” New England Journal of Medicine, vol. 376, no. 18, May 2017, pp. 1748–61. EBSCOhost, https://doi.org/10.1056/NEJMoa1614949.

APA

Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., Gigantelli, J. W., Couch, S. M., Shriver, E. M., Hayek, B. R., Hink, E. M., Woodward, R. M., Gabriel, K., Magni, G., & Douglas, R. S. (2017). Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine, 376(18), 1748–1761. https://doi.org/10.1056/NEJMoa1614949

Chicago

Smith, Terry J., George J. Kahaly, Daniel G. Ezra, James C. Fleming, Roger A. Dailey, Rosa A. Tang, Gerald J. Harris, et al. 2017. “Teprotumumab for Thyroid-Associated Ophthalmopathy.” New England Journal of Medicine 376 (18): 1748–61. doi:10.1056/NEJMoa1614949.